MedTrace Logo

Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

NCT06915779 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 241

Last updated 2025-04-08

No results posted yet for this study

Summary

The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is determined by HIV parameters.

Conditions

  • Cervical Cancer
  • Human Papillomavirus Infection
  • Human Immunodeficiency Virus
  • Cervical Dysplasia
  • Genital Warts

Sponsors & Collaborators

  • CIHR Canadian HIV Trials Network

    collaborator NETWORK

  • Women's Health Research Institute of British Columbia

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • BC Women's Hospital & Health Centre

    collaborator OTHER

  • Merck Canada Inc.

    collaborator INDUSTRY

  • University Health Network, Toronto

    collaborator OTHER

  • McGill University

    collaborator OTHER

  • University of Saskatoon

    collaborator UNKNOWN

  • British Columbia Centre for Disease Control

    collaborator OTHER_GOV

  • Vaccine Evaluation Center, Canada

    collaborator OTHER

  • British Columbia Cancer Agency

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Deborah M Money, MD, FRCSC · Dept. OB/GYN, University of British Columbia

Eligibility

Min Age
11 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2021-03-30
Completion
2021-03-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06915779 on ClinicalTrials.gov